This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Calvo, A. Articles by Green, J. E. Search for Related Content PubMed PubMed Citation Articles by Calvo, A. Articles by Green, J. E.

Adenovirus-mediated Endostatin Delivery Results in Inhibition of Mammary Gland Tumor Growth in C3(1)/SV40 T-Antigen Transgenic Mice

Laboratory of Cell Regulation and Carcinogenesis [A. C., J. E. G.] and Surgery Branch [A. L. F., S. K. L.], National Cancer Institute, NIH, Bethesda, Maryland 20892

We demonstrate the efficacy of systemic administration of a replication-defectiveadenovirus expressing endostatin (Ad-mEndo) administered during the preinvasive stage of mammary tumor development in C3(1)/T antigen transgenic mice. Mean serum levels of endostatin increased about 8-fold above that of controls and resulted in a significant decrease in tumor growth and an increase in survival. The inhibitory effect of endostatin occurred during or after the progression to invasive carcinoma. Reduced levels of vascular endothelial growth factor mRNA were found in association with high levels of endostatin. Our results demonstrate that the adenoviral induction of high levels of circulating endostatin significantly inhibits mammary tumor growth during the period when the "angiogenic switch" occurs.

This article has been cited by other articles:

				X. Li, S. P. Raikwar, Y.-H. Liu, S.-J. Lee, Y.-P. Zhang, S. Zhang, L. Cheng, S.-D. Lee, B. E. Juliar, T. A. Gardner, et al. Combination therapy of androgen-independent prostate cancer using a prostate restricted replicative adenovirus and a replication-defective adenovirus encoding human endostatin-angiostatin fusion gene. Mol. Cancer Ther., March 1, 2006; 5(3): 676 - 684. [Abstract] [Full Text] [PDF]

				L Li, Y-Z Yuan, J Lu, L Xia, Y Zhu, Y-P Zhang, and M-M Qiao Treatment of pancreatic carcinoma by adenoviral mediated gene transfer of vasostatin in mice Gut, February 1, 2006; 55(2): 259 - 265. [Abstract] [Full Text] [PDF]

				R. Liu, S. Varghese, and S. D. Rabkin Oncolytic Herpes Simplex Virus Vector Therapy of Breast Cancer in C3(1)/SV40 T-antigen Transgenic Mice Cancer Res., February 15, 2005; 65(4): 1532 - 1540. [Abstract] [Full Text] [PDF]

				C. M. Mazzanti, A. Tandle, D. Lorang, N. Costouros, D. Roberts, G. Bevilacqua, and S. K. Libutti Early Genetic Mechanisms Underlying the Inhibitory Effects of Endostatin and Fumagillin on Human Endothelial Cells Genome Res., August 1, 2004; 14(8): 1585 - 1593. [Abstract] [Full Text] [PDF]

				Q. Zhang, M. Nie, J. Sham, C. Su, H. Xue, D. Chua, W. Wang, Z. Cui, Y. Liu, C. Liu, et al. Effective Gene-Viral Therapy for Telomerase-Positive Cancers by Selective Replicative-Competent Adenovirus Combining with Endostatin Gene Cancer Res., August 1, 2004; 64(15): 5390 - 5397. [Abstract] [Full Text] [PDF]

				C. Kavanaugh and J. E. Green The Use of Genetically Altered Mice for Breast Cancer Prevention Studies J. Nutr., July 1, 2003; 133(7): 2404S - 2409. [Abstract] [Full Text] [PDF]